Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2
4(80.0%)
Phase 1
1(20.0%)
5Total
Phase 2(4)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06440525Phase 2Recruiting

A Study of RSLV-132 in Females With Sjögren's Disease

Role: lead

NCT04944121Phase 2Completed

Phase 2 Study of RSLV-132 in Subjects With Long COVID

Role: lead

NCT03247686Phase 2Completed

A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome

Role: lead

NCT02660944Phase 2Completed

A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)

Role: lead

NCT02194400Phase 1Completed

Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus

Role: lead

All 5 trials loaded